{"entity":{"id":"depmap","kind":"collection","name":"DepMap (Cancer Dependency Map)","aka":["Broad DepMap portal","DepMap portal","Cancer Dependency Map"],"tldr":"Which genes each cancer cell line cannot live without. The map of synthetic-lethal targets.","summary":"DepMap, the Cancer Dependency Map, holds genome-wide CRISPR and drug screens across more than 1,000 cancer cell lines with matched multi-omics, showing which genes each line cannot live without and therefore where synthetic-lethal targets may lie. Its releases include Chronos gene-effect scores, PRISM drug sensitivity data and CCLE omics, published quarterly by the Broad Institute under CC BY 4.0. On OnCo it is linked to the technologies CRISPR functional genomics and Synthetic lethality approaches and to the key paper Defining a Cancer Dependency Map. It is cited by the bottlenecks The undruggable drivers, Lab models that fail to predict what happens in patients, Too many combinations to test and Preclinical results do not reproduce, and by a dozen ideas on screening and model banks.","asOf":"2026-09-04","links":[{"label":"DepMap (Cancer Dependency Map)","url":"https://depmap.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["crispr-screens","synthetic-lethality-approaches"],"targets":[],"drugs":[],"companies":[],"institutions":["broad-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-depmap-tsherniak-cell-2017"],"journals":[],"dependsOn":[],"notes":[],"url":"https://depmap.org","holds":"Genome-wide CRISPR and drug screens across >1,000 cancer cell lines with multi-omics.","license":"CC BY 4.0","maintainer":"Broad Institute"},"route":"/collections/depmap/","neighbours":{"technology":[{"id":"crispr-screens","kind":"technology","name":"CRISPR functional genomics","route":"/technologies/crispr-screens/"},{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/"}],"institution":[{"id":"broad-institute","kind":"institution","name":"Broad Institute of MIT and Harvard","route":"/institutions/broad-institute/"},{"id":"wellcome-sanger","kind":"institution","name":"Wellcome Sanger Institute","route":"/institutions/wellcome-sanger/"}],"paper":[{"id":"paper-depmap-tsherniak-cell-2017","kind":"paper","name":"Defining a Cancer Dependency Map: which genes each cancer cell line cannot live without","route":"/key-papers/paper-depmap-tsherniak-cell-2017/"}],"bottleneck":[{"id":"b-preclinical-models","kind":"bottleneck","name":"Lab models that fail to predict what happens in patients","route":"/bottlenecks/b-preclinical-models/"},{"id":"b-reproducibility","kind":"bottleneck","name":"Preclinical results do not reproduce","route":"/bottlenecks/b-reproducibility/"},{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/"},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"},{"id":"b-combination-space","kind":"bottleneck","name":"Too many combinations to test","route":"/bottlenecks/b-combination-space/"}],"idea":[{"id":"idea-bio2-dormancy-selective-screen","kind":"idea","name":"A drug screen that only rewards killing sleeping cancer cells","route":"/ideas/idea-bio2-dormancy-selective-screen/"},{"id":"idea-fund-target-validation-consortium","kind":"idea","name":"A pre-competitive consortium to validate or kill academic targets before licensing","route":"/ideas/idea-fund-target-validation-consortium/"},{"id":"idea-tr2-organoid-matrix-atlas","kind":"idea","name":"A public atlas of drug-pair responses across a thousand patient-derived organoids","route":"/ideas/idea-tr2-organoid-matrix-atlas/"},{"id":"idea-tr2-synergy-ranking-engine","kind":"idea","name":"An open engine that ranks every drug pair by predicted synergy before anyone runs a trial","route":"/ideas/idea-tr2-synergy-ranking-engine/"},{"id":"idea-data-open-cell-foundation-model","kind":"idea","name":"An open foundation model of the cancer cell trained on perturbation data","route":"/ideas/idea-data-open-cell-foundation-model/"},{"id":"idea-bio2-rare-tumour-model-bank","kind":"idea","name":"An open model bank for the rare tumours nobody has models for","route":"/ideas/idea-bio2-rare-tumour-model-bank/"},{"id":"idea-tr2-reference-compound-panels","kind":"idea","name":"Every drug screen includes standard reference compounds whose performance is published","route":"/ideas/idea-tr2-reference-compound-panels/"},{"id":"idea-bio2-mechanism-defined-baskets","kind":"idea","name":"Group trials by broken mechanism, not by organ or single mutation","route":"/ideas/idea-bio2-mechanism-defined-baskets/"},{"id":"idea-bio2-metastasis-screen-standard","kind":"idea","name":"Make in vivo metastasis screens a required step in drug discovery","route":"/ideas/idea-bio2-metastasis-screen-standard/"}],"roadmap":[{"id":"drug-discovery-roadmap","kind":"roadmap","name":"Drug discovery roadmap: screening in mice → maps of dependency → designing in silico","route":"/roadmaps/drug-discovery-roadmap/"},{"id":"virtual-cell","kind":"roadmap","name":"Virtual cell roadmap: from bulk omics to a predictive model of a cancer cell","route":"/roadmaps/virtual-cell/"}],"term":[{"id":"cancer-ai-vocabulary","kind":"term","name":"Cancer AI vocabulary (CanSim terms map)","route":"/terms/cancer-ai-vocabulary/"},{"id":"cell-lines-as-proxy","kind":"term","name":"Cell lines as a proxy for patients","route":"/terms/cell-lines-as-proxy/"},{"id":"drug-response-sensitivity","kind":"term","name":"Drug response and drug sensitivity (IC50, AUC)","route":"/terms/drug-response-sensitivity/"}]}}